New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
10:36 EDTTJX, BPL, AZN, FST, URBNHigh option volume stocks: TJX BPL AZN FST URBN
News For TJX;BPL;AZN;FST;URBN From The Last 14 Days
Check below for free stories on TJX;BPL;AZN;FST;URBN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 22, 2014
10:07 EDTAZNOptions with increasing implied volatility: ORPH EXAS AZN
Subscribe for More Information
05:19 EDTAZNStocks with implied volatility movement; JRJC AZN
Subscribe for More Information
August 21, 2014
09:54 EDTAZNPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
07:47 EDTAZNPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
05:42 EDTAZNIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
07:44 EDTTJXTJX remains one of the best growth stories in retail, says UBS
UBS said TJX remains one of the best growth stories in retail with many second half catalysts. The firm cited clean inventories, eCommerce expansion, its loyalty program, and potential acceleration of international store growth. Shares of TJX are Buy rated and price target raised to $67 from $63.
August 19, 2014
12:55 EDTTJXTJX Q2 results better than feared, says Sterne Agee
Subscribe for More Information
11:53 EDTURBNAeropostale soars as Geiger returns as CEO
Subscribe for More Information
11:28 EDTTJXTJX sees Q4 EPS 90c-94c, consolidated Q4 SSS growth 1%-2%
Subscribe for More Information
11:28 EDTTJXTJX sees 2H EPS $1.71--$1.80
Subscribe for More Information
10:28 EDTTJXHigh option volume stocks
Subscribe for More Information
10:13 EDTURBNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:36 EDTTJXTJX ups FY15 adjusted EPS outlook to $3.10-$3.18, consensus $3.14
Subscribe for More Information
08:35 EDTTJXTJX sees Q3 EPS 81c-85c, consensus 85c
Subscribe for More Information
08:34 EDTTJXTJX says customer traffic was positive in July, says Q3 off to 'solid' start
08:34 EDTTJXTJX reports Q2 EPS ex-items 75c, consensus 73c
Subscribe for More Information
08:01 EDTURBNUrban Outfitters shares should be bought on weakness, says Stifel
Subscribe for More Information
07:14 EDTURBNUrban Outfitters Urban brand turnaround on track, says RBC Capital
Subscribe for More Information
07:01 EDTAZNDOJ closes investigation into PLATO Brilinta clinical trial, plans no action
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with BRILINTA tablets. The government is not planning any further action. Pascal Soriot, CEO, said: “We welcome the Department of Justice’s decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit BRILINTA offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca’s growth platforms, we remain committed to delivering the full potential of this important medicine.” As part of our continued commitment to advancing the science behind cardiovascular medicine, AstraZeneca has initiated a clinical trial program for BRILINTA, its largest program involving more than 80,000 patients worldwide.
05:24 EDTURBNUrban Outfitters upgraded to Outperform from Neutral at RW Baird
RW Baird upgraded Urban Outfitters to Outperform citing a more favorable risk/reward following the company's Q2 results. Baird highlights merchandise improvements at the namesake brand and momentum at Anthropologie and Free People. The firm raised its price target for shares to $44 from $40.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use